Search results for "inflammatory"

showing 10 items of 1845 documents

Specific norovirus interaction with Lewis x and Lewis a on human intestinal inflammatory mucosa during refractory inflammatory bowel disease

2021

Inflammatory bowel disease (IBD), including Crohn’s disease (CD) and ulcerative colitis (UC), are progressive diseases affecting millions of people each year. Flare-ups during IBD result in severe mucosal alterations of the small intestine (in CD) and in the colon and rectum (in CD and UC).

0301 basic medicineCrohn’s diseaseMaleSeverity of Illness IndexInflammatory bowel diseasechemistry.chemical_compound0302 clinical medicineMedicineIntestinal MucosaCrohn's disease0303 health sciencesMiddle AgedImmunohistochemistryUlcerative colitisQR1-502HBGA3. Good healthmedicine.anatomical_structure030220 oncology & carcinogenesisImmunohistochemistry030211 gastroenterology & hepatologyFemalegut inflammationResearch ArticleAdultCA-19-9 Antigenmedicine.drug_classLewis X AntigenRectumMonoclonal antibodyMicrobiologydigestive systemVirusHost-Microbe BiologyYoung Adult03 medical and health sciencesAntigenHumansMolecular Biologyulcerative colitis030304 developmental biologybusiness.industryNorovirus[SDV.MHEP.HEG]Life Sciences [q-bio]/Human health and pathology/Hépatology and GastroenterologySialyl-Lewis AInflammatory Bowel Diseasesmedicine.diseasedigestive system diseasesSmall intestineGastrointestinal Tract030104 developmental biologySialyl-Lewis XchemistryinflammationImmunologybusiness[SDV.AEN]Life Sciences [q-bio]/Food and Nutrition
researchProduct

Advances in the treatment of cutaneous lupus erythematosus.

2016

Lupus erythematosus (LE) is a multifactorial autoimmune disease with clinical manifestations of differing severity which may present with skin manifestations as primary sign of the disease (cutaneous lupus erythematosus, CLE) or as part of a disease spectrum (systemic lupus erythematosus, SLE). To date, no drugs are approved specifically for the treatment of CLE and only single agents have been applied in randomized controlled trials. Therefore, topical and systemic agents are used “off-label”, primarily based on open-label studies, case series, retrospective analyses, and expert opinions. In contrast, several agents, such as hydroxychloroquine, chloroquine, cyclophosphamide, azathioprine,…

0301 basic medicineCyclophosphamideDiscoid lupus erythematosusAzathioprineAntibodiesEtanerceptPolyethylene Glycols03 medical and health sciencesLupus Erythematosus DiscoidRheumatologyimmune system diseasesChloroquineMedicineHumansLupus Erythematosus SystemicMolecular Targeted TherapyPrecision Medicineskin and connective tissue diseasesRandomized Controlled Trials as TopicB-LymphocytesLupus erythematosusbusiness.industryInterleukin-6Anti-Inflammatory Agents Non-SteroidalHydroxychloroquinemedicine.diseaseBelimumab030104 developmental biologyImmunologyInterferonsbusinessBiomarkersAnti-SSA/Ro autoantibodiesmedicine.drugSignal TransductionLupus
researchProduct

Preventive effects of guanosine on intestinal inflammation in 2, 4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rats

2018

Background: Guanosine, a guanine-based purine, is an extracellular signaling molecule exerting anti-inflammatory and antioxidative effects in several in vivo and in vitro injury models. We aimed to investigate its protective effects on 2, 4-dinitrobenzene sulfonic acid (DNBS)-induced colitis in rat. Methods: Rats were divided into five groups and colitis was induced by intracolonic instillation of DNBS (15 mg/rat). Guanosine (4 or 8 mg/kg) was administered for 6 days i.p. starting the day of the colitis induction. Body weight loss, stool consistency, colon weight/length, histological analysis, myeloperoxidase activity (MPO) and pro-inflammatory cytokine levels were assessed. Immunoblotting …

0301 basic medicineDNBS ratColonmedicine.medical_treatmentInterleukin-1betaImmunologyAnti-Inflammatory AgentsGuanosineInflammationPharmacologySettore BIO/09 - FisiologiaInflammatory bowel diseaseAntioxidantsInflammatory bowel disease03 medical and health scienceschemistry.chemical_compound0302 clinical medicineIn vivomedicineAnimalsPharmacology (medical)Intestinal MucosaRats WistarColitisPurineInflammationPharmacologychemistry.chemical_classificationReactive oxygen speciesGuanosineInterleukin-6Tumor Necrosis Factor-alphaNF-kappa BColitismedicine.diseaseRats030104 developmental biologyCytokinechemistryCytokinesDinitrofluorobenzeneTumor necrosis factor alphamedicine.symptomReactive Oxygen Species030217 neurology & neurosurgeryInflammopharmacology
researchProduct

Circadian rhythms in the pathogenesis of gastrointestinal diseases

2018

The etiology of digestive pathologies such as irritable bowel syndrome (IBS), inflammatory bowel diseases (IBD) and cancer is not yet fully understood. In recent years, several studies have evidenced circadian variations in mechanisms involved in digestive health. In situations of disturbed circadian rhythms (chronodisruption) where the central clock and the peripheral clocks receive incoherent signals, the synchronicity is lost producing implications for health. This lack of coordination could alter the tissue function and cause long term damage to the organs. Life habits such as sleep, physical exercise, social interaction, and feeding times are determinants for stability and integrity of…

0301 basic medicineDigestive cancersGastrointestinal DiseasesPhysical exerciseBioinformaticsInflammatory bowel diseaseInflammatory bowel diseasePathogenesis03 medical and health sciencesCircadian ClocksmedicineHumansCircadian rhythmsCircadian rhythmHealthy LifestyleDigestive cancerIrritable bowel syndromebusiness.industryGastroenterologyLong term damageGeneral Medicinemedicine.diseaseCircadian RhythmGastrointestinal TractIrritable bowel syndrome030104 developmental biologyEditorialEtiologybusinessWorld Journal of Gastroenterology
researchProduct

Neuromodulatory effect of interleukin 1β in the dorsal raphe nucleus on individual differences in aggression

2021

Heightened aggressive behavior is considered as one of the central symptoms of many neuropsychiatric disorders including autism, schizophrenia, and dementia. The consequences of aggression pose a heavy burden on patient’s families, clinicians, and the patients themselves. At the same time, we have limited treatment options for aggression and lack mechanistic insight into the causes of aggression needed to inform new efforts in drug discovery and development. Levels of proinflammatory cytokines in the periphery or cerebrospinal fluid were previously reported to correlate with aggressive traits in humans. However, it is still unknown whether cytokines affect brain circuits to modulate aggress…

0301 basic medicineDorsal Raphe NucleusMaleSerotoninInterleukin-1betaIndividualityArticleProinflammatory cytokine03 medical and health sciencesCellular and Molecular NeuroscienceMice0302 clinical medicineDorsal raphe nucleusdorsal raphe nucleumedicinePremovement neuronal activityAnimalsHumansMolecular BiologyGene knockdownAggressionbusiness.industrymedicine.diseaseAggressionPsychiatry and Mental health030104 developmental biologySchizophreniaForebrainSettore BIO/14 - Farmacologiainterleukin 1βSerotoninmedicine.symptombusinessNeuroscience030217 neurology & neurosurgery
researchProduct

Fishing anti-inflammatories from known drugs: In silico repurposing, design, synthesis and biological evaluation of bisacodyl analogues

2017

Herein is described in silico repositioning, design, synthesis, biological evaluation and structure-activity relationship (SAR) of an original class of anti-inflammatory agents based on a polyaromatic pharmacophore structurally related to bisacodyl (BSL) drug used in therapeutic as laxative. We describe the potential of TOMOCOMD-CARDD methods to find out new anti-inflammatory drug-like agents from a diverse series of compounds using the total and local atom based bilinear indices as molecular descriptors. The models obtained were validated by biological studies, identifying BSL as the first anti-inflammatory lead-like using in silico repurposing from commercially available drugs. Several bi…

0301 basic medicineDrugBisacodylAnti-inflammatory databasemedia_common.quotation_subjectIn silico[CHIM.THER]Chemical Sciences/Medicinal Chemistry03 medical and health sciencesIn vivoMolecular descriptorDrug DiscoveryDiarylmethylpyridinesmedicine[CHIM.CRIS]Chemical Sciences/CristallographyBisacodylRepurposingComputingMilieux_MISCELLANEOUSmedia_commonAnti-inflammatory assayChemistry[CHIM.ORGA]Chemical Sciences/Organic chemistryGeneral MedicineCombinatorial chemistry[SDV.BIBS]Life Sciences [q-bio]/Quantitative Methods [q-bio.QM]3. Good health030104 developmental biologyMechanism of actionAtom-based bilinear indicesmedicine.symptomPharmacophoreTOMOCOMD-CARDD SoftwareRepurposingmedicine.drug
researchProduct

Targeted delivery of Cyclosporine A by polymeric nanocarriers improves the therapy of inflammatory bowel disease in a relevant mouse model

2017

The therapy of inflammatory bowel diseases is still rather inefficient, and about 80% of patients require surgery at some stage. Improving the treatments by more efficient medication is, therefore, an urgent medical need. The objective of this project was to demonstrate targeted delivery of Cyclosporine-A (CYA) to the inflamed areas of the intestinal mucosa after oral administration, enabling improved alleviation of the symptoms and, at the same time, reduced systemic drug absorption and associated adverse effects. As had already been demonstrated in previous studies, nano- to micrometer-sized drug particles will accumulate at inflamed mucosal areas, providing a platform for such purposes. …

0301 basic medicineDrugColonPolymersmedia_common.quotation_subjectAdministration OralBiological AvailabilityPharmaceutical Science02 engineering and technologyPharmacologyInflammatory bowel diseaseMice03 medical and health sciencesDrug Delivery SystemsPolylactic Acid-Polyglycolic Acid CopolymerIntestinal mucosaOral administrationAnimalsMedicineLactic AcidIntestinal MucosaParticle SizeAdverse effectmedia_commonDrug CarriersMice Inbred BALB CCrohn's diseasebusiness.industryGeneral MedicineInflammatory Bowel Diseases021001 nanoscience & nanotechnologymedicine.diseaseBioavailabilityDisease Models Animal030104 developmental biologyCyclosporineNanoparticlesNanocarriers0210 nano-technologybusinessPolyglycolic AcidBiotechnologyEuropean Journal of Pharmaceutics and Biopharmaceutics
researchProduct

Drug metabolism by cultured human hepatocytes: how far are we from the in vivo reality?

2004

The investigation of metabolism is an important milestone in the course of drug development. Drug metabolism is a determinant of drug pharmacokinetics variability in human beings. Fundamental to this are phenotypic differences, as well as genotypic differences, in the expression of the enzymes involved in drug metabolism. Genotypic variability is easy to identify by means of polymerase chain reaction-based or DNA chip-based methods, whereas phenotypic variability requires direct measurement of enzyme activities in liver, or, indirectly, measurement of the rate of metabolism of a given compound in vivo. There is a great deal of phenotypic variability in human beings, only a minor part being…

0301 basic medicineDrugDiclofenacmedia_common.quotation_subjectBiologyPharmacologyToxicologyGeneral Biochemistry Genetics and Molecular Biology03 medical and health sciences0302 clinical medicineCytochrome P-450 Enzyme SystemIn vivoGenetic variationmedicineHumansCells Culturedmedia_common030102 biochemistry & molecular biologyAnti-Inflammatory Agents Non-SteroidalGenetic VariationGeneral MedicineMetabolismIn vitroMedical Laboratory TechnologyDrug developmentBiochemistryLiverPharmaceutical Preparations030220 oncology & carcinogenesisMultigene FamilyHepatocytesAceclofenacDrug metabolismmedicine.drugAlternatives to laboratory animals : ATLA
researchProduct

Abacavir Induces Arterial Thrombosis in a Murine Model.

2018

Background The purinergic system is known to underlie prothrombotic and proinflammatory vascular programs, making the profile of experimental actions demonstrated by abacavir compatible with thrombogenesis. However, direct evidence of a prothrombotic effect by the drug has been lacking. Methods The present study appraised the effects of abacavir in a well-validated animal model of arterial thrombosis. The role of ATP-P2X7 receptors in the actions of the drug was also assessed, and the actions of recognized vascular-damaging agents and other nucleoside reverse-transcriptase inhibitors (NRTIs) were evaluated and compared to those of abacavir. Results Abacavir dose-dependently promoted thrombu…

0301 basic medicineDrugMaleAnti-HIV Agentsmedia_common.quotation_subject030204 cardiovascular system & hematologyPharmacologyProinflammatory cytokine03 medical and health sciences0302 clinical medicineimmune system diseasesAbacavirmedicineImmunology and AllergyAnimalsRofecoxibmedia_commonMice KnockoutDose-Response Relationship Drugbusiness.industryPurinergic receptorAntagonistvirus diseasesThrombosisPurinergic signallingmedicine.diseaseThrombosisDideoxynucleosidesDisease Models Animal030104 developmental biologyInfectious DiseasesReceptors Purinergic P2X7businessmedicine.drugThe Journal of infectious diseases
researchProduct

Cardiovascular toxicity of abacavir: a clinical controversy in need of a pharmacological explanation.

2017

: There is a long-lasting controversy surrounding an association between abacavir (ABC) and an increased risk of cardiovascular disease in HIV-positive patients. Although differing in their specifics, a number of published cohort studies and clinical trials support such an association, usually relating it to recent exposure to the drug, independently of traditional predisposing factors. However, other clinical trials have failed to reveal such a relation and have pointed to methodological differences to explain discrepancies. Significantly, the controversy has been fueled by the lack of a credible mechanism of action to justify the putative detrimental actions of ABC. There is a myriad of c…

0301 basic medicineDrugVasculitisAnti-HIV Agentsmedia_common.quotation_subjectImmunologyHIV InfectionsDiseasePharmacologyBioinformaticsProinflammatory cytokine03 medical and health sciencesParacrine signallingchemistry.chemical_compound0302 clinical medicineAbacavirImmunology and AllergyMedicineHumans030212 general & internal medicineCyclic guanosine monophosphatemedia_commonbusiness.industryAtherosclerosis030112 virologyDideoxynucleosidesClinical trialInfectious DiseaseschemistryMechanism of actionCardiovascular Diseasesmedicine.symptombusinessmedicine.drugAIDS (London, England)
researchProduct